• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nuvation Bio Inc. Class A Common Stock (NY: NUVB )

    2.760 -0.060 (-2.13%)
    Official Closing Price Updated: 7:00 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,320,303
    Open 2.780
    Bid (Size) 2.560 (1)
    Ask (Size) 2.780 (39)
    Prev. Close 2.820
    Today's Range 2.690 - 2.880
    52wk Range 1.430 - 4.160
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer
    From Nuvation Bio Inc.
    Via Business Wire
    Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference
    From Nuvation Bio Inc.
    Via Business Wire

    Performance

    YTD
    +75.80%
    +75.80%
    1 Month
    -4.50%
    -4.50%
    3 Month
    +15.48%
    +15.48%
    6 Month
    -5.48%
    -5.48%
    1 Year
    +80.39%
    +80.39%

    More News

    Read More
    Nuvation Bio to Present at the Jefferies London Healthcare Conference
    From Nuvation Bio Inc.
    Via Business Wire
    Top 4 Health Care Stocks That May Plunge This Quarter
    Via Benzinga
    Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Nuvation Bio Inc.
    Via Business Wire
    Fastenal Posts Upbeat Earnings, Joins Wells Fargo, JPMorgan And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
    From Nuvation Bio Inc.
    Via Business Wire
    Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
    From Nuvation Bio Inc.
    Via Business Wire
    Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Nuvation Bio to Present at the Cantor Global Healthcare Conference
    From Nuvation Bio
    Via Business Wire
    Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
    Via Benzinga
    Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Nuvation Bio Inc.
    Via Business Wire
    Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
    From Nuvation Bio Inc.
    Via Business Wire
    NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
    Via Benzinga
    Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
    From Nuvation Bio Inc.
    Via Business Wire
    Nuvation Bio to Present at the Jefferies Global Healthcare Conference
    From Nuvation Bio Inc.
    Via Business Wire
    NUVB Stock Earnings: Nuvation Bio Beats EPS for Q1 2024
    Via InvestorPlace
    Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
    From Nuvation Bio Inc.
    Via Business Wire
    Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Nuvation Bio Inc.
    Via Business Wire
    Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Nuvation Bio Completes Acquisition of AnHeart Therapeutics
    From Nuvation Bio Inc.
    Via Business Wire
    ProfoundBio Discovers The Joys Of Having A Wealthy Owner
    Via Benzinga
    Intel, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
    Via Talk Markets
    Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
    From Nuvation Bio Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.